Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key

Swedish Firm In ‘Active Discussions With Potential Partners,’ Deal Possible In 2023

Executive Summary

Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.

You may also be interested in...



Xbrane Drops Keytruda Rival As It Pares Down Pipeline And Personnel

Swedish biosimilars developer Xbrane Biopharma has revealed that it is dropping development of its planned Xtrudane pembrolizumab biosimilar to Keytruda, as part of a move towards a more “focused development portfolio.” At the same time, the firm has announced job cuts as part of a new cost-savings scheme designed to help the firm “achieve a positive cash flow as soon as possible.”

Xbrane: We Are Not Convinced On European IQVIA Ranibizumab Data

Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.

Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing

Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel